Pharmaceutical

Runimotamab by Genentech USA for Solid Tumor: Likelihood of Approval

Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor.

Dec 22, 2023 - 18:00
Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

Next Article

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Novo Nordisk and Broad Institute to explore drug target...

Sep 7, 2023

STAT+: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard

STAT+: Pharmalittle: End of biotech’s stock market mala...

Sep 26, 2023

Moderna and Generation Bio partner for genetic medicines development

Moderna and Generation Bio partner for genetic medicine...

Mar 25, 2023